Biogen (BIIB)
(Delayed Data from NSDQ)
$199.36 USD
-2.08 (-1.03%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $199.26 -0.10 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 161 - 180 ( 834 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
On To The Second Act: Leqembi (lecanemab) Enters The Picture With FDA Approval
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 12/16/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 122122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 121122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 12122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Clear Now? CLARITY AD Results In Hand, But CMS Remains The Key Gating Factor
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Lecanemab and the Promise of Anti-Abeta Immunotherapies-Takeaways from CTAD 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 11/18/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 112122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 111122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
The Page Turns: New CEO Appointment Announced, With Chris Viehbacher Selection
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 11122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 10/21/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L